m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG03322)
Name
Dihydrotestosterone
Synonyms
Androstanolone; STANOLONE; dihydrotestosterone; 521-18-6; Andractim; Androlone; Proteina; Anaboleen; Stanaprol; Anabolex; Protona; Neodrol; Cristerona MB; 4-Dihydrotestosterone; 17beta-Hydroxy-5alpha-androstan-3-one; 5alpha-Dihydrotestosterone; Androstanolonum; Androstanolona; DHT; 5-alpha-Dihydrotestosterone; Dihydrotestosteron; Testosterone, dihydro-; 4,5alpha-Dihydrotestosterone; 5alpha-Androstan-17beta-ol-3-one; Stanorone; Stanolon; 17beta-Hydroxyandrostan-3-one; 5alpha-DHT; LG 152; 17beta-Hydroxy-3-androstanone; [3H]dihydrotestosterone
    Click to Show/Hide
Status
Phase 4
Structure
Formula
C19H30O2
InChI
1S/C19H30O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h12,14-17,21H,3-11H2,1-2H3/t12-,14-,15-,16-,17-,18-,19-/m0/s1
InChIKey
NVKAWKQGWWIWPM-ABEVXSGRSA-N
PubChem CID
10635
TTD Drug ID
D04DJN
VARIDT Drug ID
DR00733
INTEDE Drug ID
DR0114
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Aldo-keto reductase 1C1 (AKR1C1)
YTH domain-containing family protein 1 (YTHDF1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Aldo-keto reductase 1C1 (AKR1C1) is a therapeutic target for Dihydrotestosterone. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Dihydrotestosterone through regulating the expression of Aldo-keto reductase 1C1 (AKR1C1). [1], [2]
Androgen receptor (AR)
ETS-related transcription factor Elf-3 (ELF3)
In total 2 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Androgen receptor (AR) is a therapeutic target for Dihydrotestosterone. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of Dihydrotestosterone through regulating the expression of Androgen receptor (AR). [3], [4]
Androgen receptor (AR) is a therapeutic target for Dihydrotestosterone. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of Dihydrotestosterone through regulating the expression of Androgen receptor (AR). [3], [5]
Aromatase (CYP19A1)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Aromatase (CYP19A1) is a therapeutic target for Dihydrotestosterone. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Dihydrotestosterone through regulating the expression of Aromatase (CYP19A1). [6], [7]
P-glycoprotein 1 (ABCB1)
Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary P-glycoprotein 1 (ABCB1) is a therapeutic target for Dihydrotestosterone. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Dihydrotestosterone through regulating the expression of P-glycoprotein 1 (ABCB1). [8], [9]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary P-glycoprotein 1 (ABCB1) is a therapeutic target for Dihydrotestosterone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Dihydrotestosterone through regulating the expression of P-glycoprotein 1 (ABCB1). [9], [10]
References
Ref 1 YTHDF1 links hypoxia adaptation and non-small cell lung cancer progression. Nat Commun. 2019 Oct 25;10(1):4892. doi: 10.1038/s41467-019-12801-6.
Ref 2 Human 3-alpha hydroxysteroid dehydrogenase type 3 (3Alpha-HSD3): the V54L mutation restricting the steroid alternative binding and enhancing the 20Alpha-HSD activity. J Steroid Biochem Mol Biol. 2014 May;141:135-43. doi: 10.1016/j.jsbmb.2014.01.003. Epub 2014 Jan 13.
Ref 3 ELF3 is a repressor of androgen receptor action in prostate cancer cells. Oncogene. 2014 Feb 13;33(7):862-71. doi: 10.1038/onc.2013.15. Epub 2013 Feb 25.
Ref 4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
Ref 5 An Electrophilic Deguelin Analogue Inhibits STAT3 Signaling in H-Ras-Transformed Human Mammary Epithelial Cells: The Cysteine 259 Residue as a Potential Target. Biomedicines. 2020 Oct 12;8(10):407. doi: 10.3390/biomedicines8100407.
Ref 6 Increased N6-methyladenosine causes infertility is associated with FTO expression. J Cell Physiol. 2018 Sep;233(9):7055-7066. doi: 10.1002/jcp.26507. Epub 2018 Mar 25.
Ref 7 Identifying susceptibility genes for prostate cancer--a family-based association study of polymorphisms in CYP17, CYP19, CYP11A1, and LH-beta. Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):2035-9. doi: 10.1158/1055-9965.EPI-05-0170.
Ref 8 Binding of RNA m6A by IGF2BP3 triggers chemoresistance of HCT8 cells via upregulation of ABCB1. Am J Cancer Res. 2021 Apr 15;11(4):1428-1445. eCollection 2021.
Ref 9 P-glycoprotein increases the efflux of the androgen dihydrotestosterone and reduces androgen responsive gene activity in prostate tumor cells. Prostate. 2004 Apr 1;59(1):77-90.
Ref 10 METTL3 promotes adriamycin resistance in MCF-7 breast cancer cells by accelerating pri-microRNA-221-3p maturation in a m6A-dependent manner. Exp Mol Med. 2021 Jan;53(1):91-102. doi: 10.1038/s12276-020-00510-w. Epub 2021 Jan 8.